Can heroin-dependent individuals benefit from a methadone maintenance treatment program before they drop out against medical advice? a 12-month follow-Up study

European Addiction Research

Volumn 19, Issue 3, 2013, Pages 155-164

  Wang, Peng Wei ^a,d   Wu, Hung Chi ^b   Lin, Huang Chi ^a,d   Yen, Chia Nan ^c   Yeh, Yi Chun ^a   Chung, Kuan Sheng ^b   Chang, Hsun Cheng ^c   Yen, Cheng Fang ^a,d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b Kaohisung Kai Suan Psychiatric Hospital   (Taiwan)

^c Tainan Hospital   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Abuse and dependence; Addiction; Adherence to treatment; Against medical advice; Depression; Follow up study; Heroin; Methadone; Quality of life

Indexed keywords

METHADONE;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; FEMALE; FOLLOW UP; HEROIN DEPENDENCE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE;

ADULT; DEPRESSION; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; FOLLOW-UP STUDIES; HEROIN DEPENDENCE; HUMANS; MALE; METHADONE; OPIATE SUBSTITUTION TREATMENT; PATIENT DISCHARGE; PATIENT DROPOUTS; QUALITY OF LIFE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84869885979     PISSN: 10226877     EISSN: 14219891     Source Type: Journal    
DOI: 10.1159/000342309     Document Type: Article

References (59)

1. Office of National Drug Control Policy: The Economic Costs of Drug Abuse in the United States, 1992-1998. Publ. No. NCJ-190636. Washington, Executive Office of the President, 2001.
2. Karow A, Verthein U, Pukrop R, Reimer J, Haasen C, Krausz M, Schafer I: Quality of life profiles and changes in the course of maintenance treatment among 1,015 patients with severe opioid dependence. Subst Use Misuse 2011; 46: 705-715.
3. Peles E, Schreiber S, Sason A, Adelson M: Long waiting period to enter methadone maintenance treatment: relation to patient characteristics and outcome. Eur Addict Res 2012; 18: 149-152.
4. Dole VP, Nyswander M: A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA 1965; 193: 646-650.
5. Gowing LR, Farrell M, Bornemann R, Sullivan LE, Ali RL: Brief report: methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med 2006; 21: 193-195.
6. Marsch LA: The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998; 93: 515-532.
7. Pani PP, Maremmani I, Pacini M, Lamanna F, Maremmani AG, Dell'osso L: Effect of psychiatric severity on the outcome of methadone maintenance treatment. Eur Addict Res 2011; 17: 80-89.
8. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M: Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102: 1454-1462.
9. Simpson DD, Sells SB: Effectiveness of treatment for drug use: an overview of the DARP research program. Adv Alcohol Subst Abuse 1982; 2: 7-29.
10. Nicholls L, Bragaw L, Ruetsch C: Opioid dependence treatment and guidelines. J Manag Care Pharm 2010; 16:S14-S21.
11. Gossop M, Marsden J, Stewart D, Treacy S: Outcomes after methadone maintenance and methadone reduction treatments: twoyear follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend 2001; 62: 255-264.
12. Bulloch A, Patten S: Non-adherence with psychotropic medications in the general population. Soc Psychiatry Psychiatr Epidemiol 2010; 45: 47-56.
13. Goff DC, Hill M, Freudenreich O: Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 2010; 71(suppl 2):20-26.
14. Hubbard RL, Marsden ME, Rachal JV, Harwood HJ, Cavanaugh ER, Ginzburg HM: Drug Abuse Treatment: A National Study of Effectiveness. Chapel Hill, University of North Carolina Press, 1989.
15. Oliver P, Keen J, Rowse G, Ewins E, Griffiths L, Mathers N: The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over years in a primary care-led methadone maintenance service. Addiction 2010; 105: 732-739.
16. Teesson M, Havard A, Fairbairn S, Ross J, Lynskey M, Darke S: Depression among entrants to treatment for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence, correlates and treatment seeking. Drug Alcohol Depend 2005; 78: 309-315.
17. Havard A, Teesson M, Darke S, Ross J: Depression among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS). J Subst Abuse Treat 2006; 30: 355-362.
18. Brienza RS, Stein MD, Chen M, Gogineni A, Sobota M, Maksad J, Hu P, Clarke J: Depression among needle exchange program and methadone maintenance clients. J Subst Abuse Treat 2000; 18: 331-337.
19. McLellan AT, Luborsky L, Woody GE, O'Brien CP, Druley KA: Predicting response to alcohol and drug abuse treatments. Role of psychiatric severity. Arch Gen Psychiatry 1983; 40: 620-625.
20. Darke S, Ross J, Teesson M, Lynskey M: Health service utilization and benzodiazepine use among heroin users: findings from the Australian Treatment Outcome Study (ATOS). Addiction 2003; 98: 1129-1135.
21. Schneider B: Substance use disorders and risk for completed suicide. Arch Suicide Res 2009; 13: 303-316.
22. Nunes EV, Sullivan MA, Levin FR: Treatment of depression in patients with opiate dependence. Biol Psychiatry 2004; 56: 793-802.
23. Stapleton R: Anxiety and depression among opiate users who misuse substances during treatment. Irish J Psychol Med 2011; 28: 6.
24. Comiskey CM, Cox G: Analysis of the impact of treatment setting on outcomes from methadone treatment. J Subst Abuse Treatment 2010; 39: 195-201.
25. Mancino M, Curran G, Han X, Allee E, Humphreys K, Booth BM: Predictors of attrition from a national sample of methadone maintenance patients. Am J Drug Alcohol Abuse 2010; 36: 155-160.
26. Kang S-Y, Deren S, Goldstein MF: Relationships between childhood abuse and neglect experience and HIV risk behaviors among methadone treatment drop-outs. Child Abuse Neglect 2002; 26: 1275-1289.
27. Gossop M, Griffiths P, Powis B, Strang J: Severity of dependence and route of administration of heroin, cocaine and amphetamines. Br J Addict 1992; 87: 1527-1536.
28. Chen VC, Chen H, Lin TY, Chou HH, Lai TJ, Ferri CP, Gossop M: Severity of heroin dependence in Taiwan: reliability and validity of the Chinese version of the Severity of Dependence Scale (SDS). Addict Behav 2008; 33: 1590-1593.
29. Ward J, Hall W, Mattick RP: Role of maintenance treatment in opioid dependence. Lancet 1999; 353: 221-226.
30. Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, Banys P, Hall SM: Methadone maintenance versus 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000; 283: 1303-1310.
31. Skevington SM, Lotfy M, O'Connell KA: The World Health Organization's WHOQOLBREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 2004; 13: 299-310.
32. Karow A, Reimer J, Schafer I, Krausz M, Haasen C, Verthein U: Quality of life under maintenance treatment with heroin versus methadone in patients with opioid dependence. Drug Alcohol Depend 2010; 112: 209-215.
33. Carpentier PJ, van Gogh MT, Knapen LJ, Buitelaar JK, De Jong CA: Influence of attention deficit hyperactivity disorder and conduct disorder on opioid dependence severity and psychiatric comorbidity in chronic methadone-maintained patients. Eur Addict Res 2011; 17: 10-20.
34. Eklund C, Melin L, Hiltunen A, Borg S: Detoxification from methadone maintenance treatment in Sweden: long-term outcome and effects on quality of life and life situation. Int J Addict 1994; 29: 627-645.
35. Reno RR, Aiken LS: Life activities and life quality of heroin addicts in and out of methadone treatment. Int J Addict 1993; 28: 211-232.
36. Chien CP, Cheng TA: Depression in Taiwan: epidemiological survey utilizing CES-D. Seishin Shinkeigaku Zasshi 1985; 87: 335-338.
37. Radloff LS: The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385-401.
38. Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, Strang J: The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995; 90: 607-614.
39. Yao G, Chung CW, Yu CF, Wang JD: Development and verification of validity and reliability of the WHOQOL-BREF Taiwan version. J Formos Med Assoc 2002; 101: 342-351.
40. Chau TT, Hsiao TM, Huang CT, Liu HW: A preliminary study of family APGAR index in the Chinese. Gaoxiong Yi Xue Ke Xue Za Zhi 1991; 7: 27-31.
41. Smilkstein G: The family APGAR: a proposal for a family function test and its use by physicians. J Fam Pract 1978; 6: 1231-1239.
42. Yen CF, Yang YH, Ko CH, Yen JY: Substance initiation sequences among Taiwanese adolescents using methamphetamine. Psychiatry Clin Neurosci 2005; 59: 683-689.
43. Rollnick S, Heather N, Gold R, Hall W: Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict 1992; 87: 743-754.
44. Samantaray PK, Ray R, Chandiramani K: Predictors of inpatient treatment completion of subjects with heroin dependence. Indian J Psychiatry 1997; 39: 282-287.
45. Bolker BM, Brooks ME, Clark CJ, Geange SW, Poulsen JR, Stevens MHH, White J-SS: Generalized linear mixed models: a practical guide for ecology and evolution. Trends Ecol Evol 2009; 24: 127-135.
46. Shek DT, Ma CM: Longitudinal data analyses using linear mixed models in SPSS: concepts, procedures and illustrations. ScientificWorldJournal 2011; 11: 42-76.
47. Cnaan A, Laird NM, Slasor P: Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Statist Med 1997; 16: 2349-2380.
48. Spybrook J, et al: Optimal design for longitudinal and multilevel research: documentation for the optimal design software version 3.0 (2011). Available from http://pikachu. harvard.edu/od/or from www.wtgrantfoundation. org.
49. Knowlton AR, Latkin CA, Schroeder JR, Hoover DR, Ensminger M, Celentano DD: Longitudinal predictors of depressive symptoms among low income injection drug users. AIDS Care 2001; 13: 549-559.
50. Nunes EV, Levin FR: Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 2004; 291: 1887-1896.
51. Woody GE, O'Brien CP, Rickels K: Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin in combination with methadone. Am J Psychiatry 1975; 132: 447-450.
52. Carpenter KM, Smith JL, Aharonovich E, Nunes EV: Developing therapies for depression in drug dependence: results of a stage 1 therapy study. Am J Drug Alcohol Abuse 2008; 34: 642-652.
53. George S: Review: Methadone increases retention and reduces heroin use compared with non-pharmacological maintenance. Evid Based Ment Health 2010; 13: 26.
54. Li XL, Tan HZ, Sun ZQ: Quality of life for drug abusers accepting methadone maintenance treatment. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008; 33: 601-605.
55. De Maeyer J, Vanderplasschen W, Lammertyn J, van Nieuwenhuizen C, Sabbe B, Broekaert E: Current quality of life and its determinants among opiate-dependent individuals five years after starting methadone treatment. Qual Life Res 2011; 20: 139-150.
56. Darke S: Self-report among injecting drug users: a review. Drug Alcohol Depend 1998; 51: 253-263, 267-258.
57. Jackson CT, Covell NH, Frisman LK, Essock SM: Validity of self-reported drug use among people with co-occurring mental health and substance use disorders. J Dual Diagn 2005; 1: 49-63.
58. Reisinger HS, Schwartz RP, Mitchell SG, Peterson JA, Kelly SM, O'Grady KE, Marrari EA, Brown BS, Agar MH: Premature discharge from methadone treatment: patient perspectives. J Psychoactive Drugs 2009; 41: 285-296.
59. Gu J, Xu H, Lau JTF, Hao Y, Zhong Y, Fan L, Zhao Y, Hao C, Ling W: Misconceptions predict dropout and poor adherence prospectively among newly admitted first-time methadone maintenance treatment clients in Guangzhou, China. Addiction 2012; 107: 1641-1649.